In AML, elevated c-myc and MCL1 contribute to resistance, and targeting c-Myc by 10058-F has been proposed as a feasible approach to overcome MCL1 inhibitor resistance [118]. The gene discussed is MCL1; the disease is acute myeloid leukemia.